coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Greater Wealden PCN, Wealden · Health Inequalities Profile

    PCN U36842 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 5 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    60,579

    Registered population

    54.9% aged 18–64

    27.1%

    Aged 65+

    ICB 21.9% · England 17.9%

    3.6%

    Ethnic minority (non-White)

    1.1% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    10,327

    Hypertension register

    +7.71% in 3 yrs · England +5.60%

    473

    SMI register

    29.2% of Wealden's

    913

    COPD register

    Reviews +18.12% in 3 yrs

    Forecast to 2030

    12,467

    Hypertension patients, 2030

    +2,140 on today

    68.6%

    QRISK ≥20% on statins, 2030

    +4.84pp over 3 yrs

    7.1%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    57.5%
    High-risk lipid therapy trails England.

    Lipid-lowering therapy covers 57.5% of QRISK ≥ 20% patients (England 63.6%) and 63.0% of CKD patients (England 70.3%), which may reflect recall gaps.

    -5.1%
    COPD, dementia and LD registers shrank.

    Over 2023 to 2025, COPD prevalence changed by -5.1% (England +2.6%), dementia -2.0% (England +6.0%), and learning disability -0.2% (England +5.4%), suggesting coding checks.

    93.3%
    Strong blood pressure and COPD reviews.

    Recent blood pressure recording reaches 93.3% (England 90.0%, Wealden 92.0%) and annual COPD reviews reach 80.3% (England 76.4%), showing strong review delivery.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Registered patients aged 65+ reach 27.1%, exceeding England by 9.2 percentage points

    Greater Wealden PCN serves 60,579 registered patients across 5 practices. The population is older than benchmarks: 27.1% (16,393 patients) are aged 65+, above Wealden (25.3%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Patients aged 18–64 account for 54.9% and aged 0–17 account for 18.0%. Census usual residents in associated areas are 96.4% White, compared with Wealden (96.0%), NHS Sussex Integrated Care Board (91.0%) and England (81.1%), with a 3.6% ethnic minority share. This older age profile may increase frailty demand. Ethnicity reflects resident Census data, not GP registration.

    Age profile

    0–1718.0%
    18–6454.9%
    65+27.1%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White96.4%
    Mixed1.6%
    Asian1.1%
    Other0.4%
    Black0.4%

    Older people · falls rows are Wealden local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Wealden LA)2,2462,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)82.6%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)62.6%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Wealden LA)9589819552024/25
    Falls deaths, all ages, per 100,000 (Wealden LA)8.614.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Registered patients in Core20 stand at 0.0% across an average deprivation decile of 7.4

    The PCN has an average Index of Multiple Deprivation decile of 7.4 (Wealden 7.1, NHS Sussex Integrated Care Board 6.1, England 5.5). Across the PCN, 0.0% of registered patients live in Core20 areas (Wealden 1.7%, England 21.0%), yielding 0 estimated Core20 patients across 53 associated LSOAs. Captured practice deciles span from 6.5 at Herstmonceux Integrative Health Centre to 7.7 at The Meads Surgery. Zero Core20 representation indicates health inequalities work may need to target specific clinical cohorts or rural pockets rather than national area deprivation.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Meads0.0% · 0 patients
    Bird-in-eye0.0% · 0 patients
    Wealden Ridge0.0% · 0 patients
    Buxted0.0% · 0 patients
    Herstmonceux0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    473

    SMI register

    0.77% recorded prevalence

    339

    Learning disability register

    0.55% recorded prevalence

    34

    Care homes, 1,311 beds

    In the PCN catchment

    8.8%

    Provide unpaid care

    Wealden, Census 2021

    Severe mental illness register prevalence is 0.8% (473 patients) and learning disability is 0.6% (339 patients), alongside 34 catchment care homes with 1,311 beds. Catchment bed counts do not confirm registered residents. With severe mental illness below England (1.0%) and learning disability matching England (0.6%), proactive annual health reviews and structured care-home outreach are key priorities to sustain.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 0.8% against 1.0% in England. Annual blood pressure checks reach 87.9% and BMI checks 86.5%, though Herstmonceux Integrative Health Centre recorded 69.0% for blood pressure. Published individual indicators cannot confirm full check completion.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    10,327

    Hypertension register

    +7.71%

    Register growth, 3 yrs

    Wealden +5.15% · England +5.60%

    +5.89pp

    BP control, under 80

    ≤140/90 · +3.23pp aged 80+

    +2,140

    More patients by 2030

    Forecast 12,467 (19.60%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 16.9% (10,327 patients), below Wealden (17.7%) but above England (15.2%) and NHS Sussex Integrated Care Board (16.3%), with non-age-adjusted register gaps spanning -1,101 to +377 patients. A projection points to 12,467 patients by 2030, an increase of 2,140 (about 2,100), though its methodology is unverified. Recent blood pressure checks reach 93.3% (England 90.0%), and control to threshold is 69.4% (England 70.3%), with control in patients under 80 at 66.9% (England 67.8%). Blood pressure recording exceeds national levels while control slightly trails England, indicating clinical review could focus on treatment titration.

    Lipids and statins

    Lipid-lowering therapy reaches 57.5% for patients with QRISK ≥ 20% (England 63.6%, NHS Sussex Integrated Care Board 60.0%), 63.0% in chronic kidney disease (England 70.3%), and 79.9% in diabetes with cardiovascular disease (England 84.4%). Lower coverage across these cohorts could reflect recall gaps, which clinical register audits can test.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026119,062£2.00£2.42£1.86£238,124
    Cardiovascular (all), 2025162,443£2.97£3.32£3.33£482,456

    In 2026, the PCN prescribed 119,062 lipid-regulating drug items at £2.00 per item (England £1.86, Wealden £2.18, NHS Sussex Integrated Care Board £2.42). The PCN spends £16,669 more than at England's unit cost, across 119,062 items, but £50,006 less than at NHS Sussex Integrated Care Board's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +14.13%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −1.50%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 1.5% (913 patients; Wealden 2.0%, England 1.9%), and prevalence fell 5.1% over three years (Wealden +2.6%, England +2.6%). COPD reviews rose +18.1% (England +2.8%) to 80.3% (England 76.4%). Asthma prevalence is 7.1% (4,100 patients; England 6.6%), but review coverage is 62.1% against 63.5% in Wealden and 65.7% in England. This leaves 1,553 patients (about 1,600) without a recorded review.

    Cancer register and children's immunisation

    The cancer register records 3,114 patients (5.1% prevalence against 3.8% in England), growing +18.0% over 2023 to 2025 (England +9.0%). For childhood immunisations, age-5 MMR dose 1 reaches 95.6% (cohort 137), exceeding the 95.0% target. However, same-cohort MMR dose 2 drops 4.4 pp to 91.2%, while MMR dose 1 at 24 months is 88.4%. This drop-off indicates an operational need to strengthen pre-school recall before school entry.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months89.8%

    England 91.0%

    6-in-1 complete primary course at 24 months91.5%

    England 92.2%

    MMR dose 1 at 24 months88.4%

    England 88.3%

    MMR dose 2 at age 591.2%

    England 82.8%

    4-in-1 pre-school booster at age 591.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In Greater Wealden PCN, recorded cancer prevalence is 5.1% (3,114 patients; England 3.8%), rising +18.0% over 2023 to 2025 (England +9.0%). Across the wider health system, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 in 2022 (4,799 of 8,209; England 55.3%), below the 75.0% national ambition by 2028, requiring about 1,360 additional early-stage diagnoses each year. Known-stage completeness was 64.3% (8,209 of 12,766 registered cases; England 67.0%). These ICB figures describe wider health system staging rather than PCN performance.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), East Sussex Healthcare NHS Trust achieved 67.0% on the 62-day cancer referral to treatment standard (standard 85.0%), below Maidstone and Tunbridge Wells NHS Trust (87.4%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), but above University Hospitals Sussex NHS Foundation Trust (65.2%). The trust met the 28-day faster diagnosis standard at 84.2% (standard 75.0%) and the 31-day treatment standard at 98.2% (standard 96.0%). In Jul 2026, 6.5% waited 6+ weeks for MRI and 0.5% for CT (England 21.4% and 9.9%). These acute trust figures describe hospital provider performance, not PCN activity.

    Pathways within standard (%)East Sussex HealthcareSussexMaidstone and Tunbridge WellsSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)84.2074.0181.7879.2979.32
    31-day treatment (96%)98.1976.7998.3590.4592.50
    62-day referral to treatment (85%)67.0465.2087.4371.5171.16
    Diagnostic waits over 6 weeks (%)East Sussex HealthcareSussexMaidstone and Tunbridge WellsEngland
    MRI6.485.620.9221.40
    CT0.488.570.519.92
    Echocardiography21.940.392.5728.48
    Colonoscopy0.7439.3519.8030.83
    Gastroscopy0.3120.0224.0329.02
    All 15 DM01 tests5.2712.956.4223.14
    Community services activityEast Sussex residentsSurrey and Sussex ICB
    Care contacts100,740309,615
    Referrals17,28566,930
    Patients with a contact25,88085,660

    Community services (residents of East Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 68% of community service contacts among Wealden residents (68,465 of 100,740 contacts). This borough-level activity reflects community service contacts among older residents, although activity is not captured at PCN level.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    QOF vaccination achievement spans 80 pp across practices, from 20.0% to 100.0%

    In 2025/26, QOF vaccination and immunisation achievement spans 80 pp across practices, from 20.0% at Buxted Medical Centre to 100.0% at The Meads Surgery (England 55.2%). Clinical-domain achievement is 72.4% at Herstmonceux Integrative Health Centre and 100.0% at The Meads Surgery (England 97.1%). This variation could reflect local recall workflows, testable by practice protocol audits.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    The Meads Surgery1020.049.7%72.9%82.2%
    Bird-in-eye1270.055.4%84.6%80.8%
    Wealden Ridge1030.046.4%85.4%77.3%
    Herstmonceux1120.046.3%79.8%70.8%
    Buxted1230.027.5%55.0%63.4%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWealdenAssetPCNWealden
    Care homes (catchment)34 (1,311 beds)n/aSchools (catchment)63n/a
    Children's centres12Places of worship92161
    Libraries27Food banks (VCS)n/a1
    Homelessness support (VCS)22Day centres (VCS)16
    Children and young people (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)2940Primary academies48

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Asthma review coverage is 62.1% across 4,100 patients, below Wealden (63.5%, 1.4 pp below) and England (65.7%, 3.6 pp below), leaving 1,553 patients (about 1,600) unreviewed. For discussion: practices could run a single-template asthma recall and offer flexible review slots to reach unreviewed patients. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD and respiratory register validation

    COPD prevalence is 1.5% (913 of 60,579 patients), below England (1.9%) and Wealden (2.0%), with a non-age-adjusted gap of +235 to +299 patients after falling 5.1% over 2023 to 2025. For discussion: practices could search for patients with repeated respiratory prescribing lacking a COPD code and review diagnostic pathways. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Lipid-lowering therapy recall in high-risk cohorts

    Lipid-lowering therapy is 57.5% in QRISK ≥ 20% (England 63.6%, 6.0 pp below; ICB 60.0%), 63.0% in CKD (England 70.3%, 7.3 pp below), and 79.9% in diabetes with CVD (England 84.4%). Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older population proactive care review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Practice vulnerability register audit (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI health check review (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension therapy review (p5)Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school MMR recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Early cancer diagnosis pathway review (p7)Cancers diagnosed at stage 1 or 2 (All cancer sites)—ICB
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD and respiratory register validation (p12)COPD register · COPD: QOF prevalence · Registered populationCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Lipid-lowering therapy recall in high-risk cohorts (p12)Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15